SADDLE RIVER, N.J.--(BUSINESS WIRE)--PDI, Inc. (NASDAQ: PDII), a pioneer in providing contract sales and commercial services to the biopharmaceutical industry, today announced the appointment of ...

PARSIPPANY, N.J., Dec. 22, 2015 /PRNewswire/ -- PDI, Inc.(PDII) today reported that as the Company transitions to focusing solely on its molecular diagnostics operations, Nancy Lurker has resigned as ...

PDI, Inc. PDII incurred operating loss of 44 cents in the second quarter of 2015, narrower than the Zacks Consensus Estimate of loss of 46 cents. Loss however winded year over year from 8 cents loss ...

PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, today announced that its Interpace Diagnostics subsidiary has entered the ...

PDI, Inc. PDII posted fourth-quarter 2014 operating loss of 27 cents per share, narrower than the Zacks Consensus Estimate loss of 50 cents but wider than the loss of 14 cents in the year-ago quarter.

NEW YORK--(BUSINESS WIRE)--Prolias Technologies, Inc. has filed suit against PDI Inc. (NASDAQ: PDII), a New Jersey-based company. PDI Inc. is alleged to have engaged breach of contract, breach of ...

PDI, Inc. (Nasdaq: PDII) today announced the signing of a collaboration agreement with a privately held molecular diagnostics company (the Company) to commercialize the Company's molecular diagnostic ...

“With PD One, pharmaceutical marketers have a new tool that bridges the gap between the direct sales model and digital marketing, creating an entirely new communication channel to more effectively ...

PDI, Inc. (PDII) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion, Nancy Lurker, Chief Executive Officer of PDI, Inc. (PDII), will preside over the NASDAQ ...

PDI provides commercialization services for established and emerging biopharmaceutical companies. The Company is dedicated to maximizing the return on investment for its clients by providing strategic ...